Dana Farber Cancer Institute (DFCI) — Boston, Massachusetts

Dana Farber Cancer Institute (DFCI) is a clinical research site located in Boston, Massachusetts, United States 02215.

Crixeo Health Trust Score: 79/100 (FAIR). This profile has not yet been claimed by the site owner.

Dana Farber Cancer Institute (DFCI) has participated in 12 clinical trials with 2 currently active.

Therapeutic areas: Acute Myeloid Leukemia, Myelodysplastic Syndromes, Carcinoma, Renal Cell.

Sponsors: Pfizer, Gilead Sciences, Genzyme, a Sanofi Company.

Sponsor Feasibility Report

Trust Score: 79/100. Verification status: Crixeo Accredited. Patient reviews: 0. Complaints: 0.

Frequently Asked Questions

What is the Trust Score for Dana Farber Cancer Institute (DFCI)?

Dana Farber Cancer Institute (DFCI) has a Crixeo Trust Score of 79/100 (FAIR). Trust Scores reflect trial volume, sponsor diversity, patient reviews, address verification, and accreditation status.

How many clinical trials has Dana Farber Cancer Institute (DFCI) conducted?

Dana Farber Cancer Institute (DFCI) has 12 clinical trials on record, with 2 currently active. Their work covers Acute Myeloid Leukemia, Myelodysplastic Syndromes, Carcinoma, Renal Cell.

Is Dana Farber Cancer Institute (DFCI) accredited by Crixeo Health?

Yes — Dana Farber Cancer Institute (DFCI) holds Crixeo Accreditation, the quality standard for clinical research sites. Accredited sites have verified compliance documents, strong patient reviews, and sponsor transparency.

Can I submit a review or complaint about Dana Farber Cancer Institute (DFCI)?

Yes. Patients and trial participants can submit reviews and file complaints directly on this profile page. All submissions are reviewed before publication.